Advertisement
Canada markets close in 58 minutes

  • S&P/TSX

    21,771.24
    +62.80 (+0.29%)
     

  • S&P 500

    4,960.55
    -50.57 (-1.01%)
     

  • DOW

    37,910.38
    +135.00 (+0.36%)
     

  • CAD/USD

    0.7272
    +0.0009 (+0.12%)
     

  • CRUDE OIL

    83.17
    +0.44 (+0.53%)
     

  • Bitcoin CAD

    88,275.64
    +1,439.84 (+1.66%)
     

  • CMC Crypto 200

    1,379.88
    +67.26 (+5.12%)
     

  • GOLD FUTURES

    2,411.90
    +13.90 (+0.58%)
     

  • RUSSELL 2000

    1,931.90
    -11.06 (-0.57%)
     

  • 10-Yr Bond

    4.6170
    -0.0300 (-0.65%)
     

  • NASDAQ

    15,251.64
    -349.86 (-2.24%)
     

  • VOLATILITY

    19.29
    +1.29 (+7.17%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

Adicet Bio
·1 min read

MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference.

Details of the event are as follows:

Panel:

Gamma Delta CART-Cells, and “Squeezed” T-cells

Date:

Thursday, April 15, 2021

Time:

1:00 – 1:55 PM ET

Format:

Panel moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com